hRELT MAb (Cl 238104 (25 ug)

Background: RELT/TNFRSF19L

RELT (Receptor Expressed in Lymphoid Tissues) is a type I transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily (TNFRSF) and has been designated TNFRSF19-like (TNFRSF19L) (1, 2). It is primarily expressed in hematopoietic tissues and peripheral blood leukocytes. Human RELT cDNA encodes a 430 amino acid (aa) residue precursor protein with a putative 26 aa signal peptide, a 136 aa extracellular domain containing one TNF receptor cysteine-rich domain and one potential N-linked glycosylation site, a 21 aa transmembrane domain and a 247 aa cytoplasmic region containing no death domain. Human RELT shares 85% and 96% aa sequence homology with mouse RELT (Accession # BAC40459) and macaque RELT (Accession # Q9N092), respectively. Among TNFRSF members, the RELT extracellular domain is most closely related to that of TNFRSF19 and OX40. RELT has been shown to exclusively bind the adaptor protein TNF receptor-associated factor 1 (TRAF1). However, it has also been shown to activate the NF-kappa B pathway independently of TRAFs. Immobilized RELT can co‑stimulate T‑cell proliferation in the presence of CD3 signaling, suggesting a potential regulatory role in immune response.